New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2013
11:11 EDTNI, CWH, AUXL, BDBD, ENDPHigh option volume stocks: BDBD CWH ENDP AUXL NI
News For BDBD;CWH;ENDP;AUXL;NI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
09:34 EDTBDBDBoulder Brands appoints Timothy Kraft as Chief Legal Officer
Boulder Brands announced Timothy Kraft has been appointed Chief Legal Officer and Secretary, effective December 16. Kraft has been a member of the Boulder Brands legal team since 2009.
09:11 EDTENDPEndo price target raised to $90 from $77 at Sterne Agee
Subscribe for More Information
December 16, 2014
16:53 EDTAUXLAuxilium updates court findings in Actavis testosterone gel patent suit
Auxilium (AUXL) disclosed in a filing that as previously disclosed, on May 23 , Auxilium Pharmaceuticals, and FCB I LLC, as licensor of Testim, filed a lawsuit in the U.S. District Court for the District of New Jersey against Actavis (ACT) for infringement of FCBís 10 patents listed in the Orange Book as covering Testim testosterone gel. The lawsuit was filed in response to a notice letter, dated April 12, 2012, sent by Actavis Laboratories, regarding its filing with the U.S. Food and Drug Administration of an Abbreviated New Drug Application for a generic 1% testosterone gel product. This letter also stated that the ANDA contained Paragraph IV certifications with respect to the nine patents listed in the Orange Book on that date as covering Testim. The companyís lawsuit filed against Actavis initially involved those nine patents, as well as a 10th patent covering Testim that was issued on May 15, 2012 and is listed in the Orange Book. By the time that the trial commenced in September 2014, the parties had agreed to remove all but one of those patents from the litigation, with the trial focused solely on claim 3 of U.S. Patent # 7,608,607 . The trial commenced in September 2014 and closing arguments occurred in November 2014. On December 16 , the company learned that Judge Linares held that claim 3 of the Ď607 patent is invalid for obviousness. The Judge also found claim 3 invalid for derivation and improper inventorship, but he declined to rule on whether correction of inventorship would be appropriate because it would be futile in light of his ruling on obviousness. Auxilium believes that Actavis is now free to enter the market with its testosterone gel product once it obtains approval from the FDA. At this time, Auxilium is not aware of Actavis having received tentative approval or final approval from the FDA for its testosterone gel product. Auxilium is analyzing the District Courtís opinion and will explore its available options with regard to this matter.
08:58 EDTAUXL, ENDPEndo a top pick for 2015, says Sterne Agee
Subscribe for More Information
December 11, 2014
17:04 EDTENDP, AUXLEndo registration statement relating to Auxilium declared effective by SEC
Subscribe for More Information
December 9, 2014
07:08 EDTENDPEndo completes acquisition of rights to Natesto from Trimel BioPharma
Endo International announced the completion of the acquisition of rights to Natesto, a testosterone nasal gel, the first and only testosterone nasal gel for replacement therapy in adult males diagnosed with hypogonadism, from Trimel BioPharma, a wholly-owned subsidiary of Trimel Pharmaceuticals for $25M including additional payments upon the achievement of certain regulatory and sales milestones. Endo will collaborate with Trimel on all regulatory and clinical development activities regarding Natesto. Endo intends to launch the product, through its Endo Pharmaceuticals subsidiary, in the Q1 of 2015.
07:07 EDTBDBDBoulder Brands valuation provides attractive entry point, says Piper Jaffray
Subscribe for More Information
December 8, 2014
09:32 EDTENDPSyneron Medical signs agreement with AMS to supply holmium laser for urology
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use